(Q36388538)

13 August 2017

Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity (English)

1 reference

13 August 2017

3

James L Gulley

1 reference

13 August 2017

Ravi A Madan

1

1 reference

13 August 2017

Christopher R Heery

series ordinal

2

1 reference

13 August 2017

language of work or name

1 reference

1 October 2012

1 reference

13 August 2017

1 reference

13 August 2017

1

1 reference

13 August 2017

7

1 reference

13 August 2017

1167-1168

1 reference

Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494633

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494633

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494633

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494633

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494633

Multiple costimulatory modalities enhance CTL avidity

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494633

CTLA-4: new insights into its biological function and use in tumor immunotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494633

Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494633

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

21 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23170267

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23170267

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4161/ONCI.20591

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

23170267

1 reference